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AbstrACt 
background Many studies identify factors that contribute 
to renal prescribing errors, but few examine how 
healthcare professionals (HCPs) detect and recover from 
an error or potential patient safety concern. Knowledge 
of this information could inform advanced error detection 
systems and decision support tools that help prevent 
prescribing errors.
Objective To examine the cognitive strategies that 
HCPs used to recognise and manage medication-related 
problems for patients with renal insufficiency.
Design HCPs submitted documentation about medication-
related incidents. We then conducted cognitive task 
analysis interviews. Qualitative data were analysed 
inductively.
setting Inpatient and outpatient facilities at a major US 
Veterans Affairs Medical Centre.
Participants Physicians, nurses and pharmacists who 
took action to prevent or resolve a renal-drug problem in 
patients with renal insufficiency.
Outcomes Emergent themes from interviews, as related 
to recognition of renal-drug problems and decision-making 
processes.
results We interviewed 20 HCPs. Results yielded a 
descriptive model of the decision-making process, 
comprised of three main stages: detect, gather information 
and act. These stages often followed a cyclical path due 
largely to the gradual decline of patients’ renal function. 
Most HCPs relied on being vigilant to detect patients’ 
renal-drug problems rather than relying on systems to 
detect unanticipated cues. At each stage, HCPs relied on 
different cognitive cues depending on medication type: for 
renally eliminated medications, HCPs focused on gathering 
renal dosing guidelines, while for nephrotoxic medications, 
HCPs investigated the need for particular medication 
therapy, and if warranted, safer alternatives.
Conclusions Our model is useful for trainees so they can 
gain familiarity with managing renal-drug problems. Based 
on findings, improvements are warranted for three aspects 
of healthcare systems: (1) supporting the cyclical nature of 
renal-drug problem management via longitudinal tracking 
mechanisms, (2) providing tools to alleviate HCPs’ heavy 
reliance on vigilance and (3) supporting HCPs’ different 
decision-making needs for renally eliminated versus 
nephrotoxic medications. 
IntrODuCtIOn
Many research studies have adequately 
assessed prevalence and factors contributing 
to medication errors,1–4 but very few exam-
ined how healthcare professionals detect and 
manage safety concerns.5 Such knowledge 
strengths and limitations of this study
 ► Cognitive task analysis (CTA) was utilised to uncover 
healthcare professionals’ internal decision-making 
process and cues they used to recognise and man-
age renal-drug problems.
 ► Multiple methods were used to aid participants’ re-
call accuracy about the incidents, using an adapted 
critical decision method in which participants were 
(a) asked to document important details as soon as 
they identified a renal-drug problem and (b) encour-
aged to access patient’s electronic health record 
during CTA interviews to aid recall of the incident.
 ► Safety incidents were selected and rigorously anal-
ysed by an interdisciplinary team that included phy-
sicians, two human factors experts, a pharmacist 
researcher and a clinical pharmacist.
 ► Healthcare professionals voluntarily chose which 
incidents to submit to the research team for con-
sideration, and may have submitted incidents in 
which they felt most confident about their actions. 
This could have influenced the type of incidents we 
studied.
 ► We intended to compare cognitive cues used by 
prescribers versus non-prescribers; however, due to 
the wide variation in incidents, we could not direct-
ly compare them and no notable differences were 
found.
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would inform more effective error detection systems and 
decision support tools, which can aid error prevention.5 
Renal-drug problems in particular would benefit from 
such knowledge due to their known risks for patient 
harm. Medications that are renally eliminated or neph-
rotoxic require dose adjustments and substitutions to 
prevent drug accumulation, renal injury and adverse 
effects for patients with renal insufficiency.6 Nonetheless, 
rates of inappropriate prescribing range from 9.4% to 
81.1% in this patient population across various health-
care settings.1 2 7 8 The clinical implications of such errors 
are serious. For example, 10% of patients with renal insuf-
ficiency experienced an adverse drug event (ADE).9 Of 
these ADEs, 91% were considered preventable and 51% 
were serious.9 Despite the availability of renal function 
estimators in electronic health records (EHRs), patients’ 
renal impairment is often overlooked when making medi-
cation-related decisions.3 4 10–13 Lack of knowledge about 
the need to adjust a medication’s dosage is a common 
cause of prescribing errors in patients with renal insuf-
ficiency.14–16 Why these errors persist, and what can be 
done to prevent them, are important questions. Part 
of the answer relies on understanding how healthcare 
professionals (HCPs) recognise and address safety situa-
tions that involve renal-drug problems.
The cognitive strategies that HCPs use in deci-
sion-making are ill-defined due to their implicit nature. 
Experts in the medical research field have shown that 
if such strategies are made explicit, errors might be 
dramatically reduced.5 17 Human factors experts have 
also emphasised the importance of identifying cognitive 
cues to be able to design systems that account for human 
limitations, enhance human performance and improve 
safety.18 One underused approach to understanding 
HCPs’ decision-making strategies is cognitive task anal-
ysis (CTA).5 17 19 20 The objective of this research was to 
examine the cognitive strategies that HCPs use to identify 
and manage renal-drug problems among patients with 
renal insufficiency. This research is part of a larger study 
that examined decision-making for two other types of 
medication incidents: adverse drug reactions and drug-
drug interactions. Previously, we published a methods 
paper that describes how we adapted CTA for this 
research.19 The present article presents results for HCPs’ 
decision-making regarding renal-drug problems.
MethODs
setting
This study was conducted at a major US Veterans Affairs 
(VA) Medical Centre. The VA’s computerised physician 
order entry (CPOE) system provides an alert about 
patients’ renal impairment and requires HCPs to click 
‘OK’ to acknowledge the content of the alert, but, except 
for metformin, does not offer real-time renal-drug alerts 
for specific medication orders. When patient laboratory 
results are available in VA’s EHR, serum creatinine and 
estimated glomerular filtration rate (eGFR) are displayed 
automatically on a ‘labs tab’ and the latter is based on stan-
dardised body surface area with units of ml/min/1.73 m2. 
The eGFR reported to prescribers is based on the modi-
fication of diet in renal disease equation and is adjusted 
for isotope dilution mass spectrometry traceable assays.21
study design
We used CTA methods, which in other industries, are 
commonly used to identify strategies and cognitive infor-
mation cues that people use to solve problems.22 23 We 
used the CTA approach to uncover HCPs’ internalised 
thinking, renal-drug problem recognition and clinical 
management processes that would typically be implicit 
and otherwise unarticulated.24–26 As described elsewhere, 
we adapted and used a specific type of CTA - the critical 
decision method -19 a specialised interview technique that 
is commonly used in CTA studies.27 28 We adapted this 
method by (1) asking HCPs to record key details on a 
standardised ‘incident card’ as soon as they became aware 
of a renal-drug problem and (2) encouraging HCPs to 
access EHR during CTA interview, to aid their recall of 
the incident.
Participant recruitment and sampling
All inpatient and outpatient practising physicians, nurse 
practitioners and pharmacists involved in the clinical care 
of patients were invited to participate via emails, flyers 
and follow-up phone calls. A research team member, who 
had no clinical or managerial roles, was responsible for 
recruitment. We did not seek to study nor quantify the 
incidence of renal-drug problems, and instead focused on 
critical incidents where HCPs detected a safety concern 
and took action to manage the renal-drug problem. 
Thus, consistent with the critical decision method tech-
nique for CTA,19 we purposely sampled from HCPs who 
encountered and acted on a renal-drug safety problem. 
Our goal sample size was 20 HCPs, which is considered a 
relatively large sample in qualitative studies.29 A study by 
Fusch and Ness found that qualitative data saturation is 
often reached within 12 participants,29 but we intention-
ally sampled more because we expected a variety of renal-
drug incidents.19 We stratified recruitment to include the 
same number of prescribers (physicians and nurse practi-
tioners) and pharmacists.
Participants completed a voluntary, written consent 
prior to any study data collection: consent occurred 
before participants submitted any incidents.
Data collection
Capture of renal-drug problems
Participants completed incident cards19 when they 
encountered a renal-drug issue that warranted their atten-
tion. This card helped collect key details to aid their recall 
during the interview. For example, the card captured how 
the participant first became aware of the problem, what 
types of electronic resources or clinical consultations 
were used to help with decision-making and what actions 
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were taken to mitigate safety risks. HCPs submitted inci-
dent cards via printed copy or secure email.
Problem selection
A physician, pharmacist and human factors expert on 
the research team reviewed each incident card to deter-
mine eligibility for an interview with the HCP. The team 
selected incidents in which the issue required great exper-
tise, could potentially cause patient harm or may be more 
challenging for trainees to resolve. Further details about 
interview eligibility and case selection is provided in the 
methods article by Russ et al.19
Interview process
Interviews were conducted within 2 to 4 weeks after inci-
dence occurrence.19 We sought to aid HCPs’ recall of the 
incident by having participants: (1) document important 
details in writing as soon as they encountered a renal-drug 
incident, then refer to that document during the inter-
view and (2) access the patient’s EHR during interviews. 
Semi-structured interviews were scheduled for 60 min. 
Critical decision method interviews were conducted in 
four phases: (1) collect a brief summary of the incident, 
(2) construct a broad timeline of events, (3) ask about 
details that influenced the participant’s decision-making 
process and (4) ask hypothetical (‘what if’) questions to 
gain further insights regarding the significance of cogni-
tive cues and strategies.28 The interview guide is available 
elsewhere.19 Interviews were audio recorded and tran-
scribed. Example questions were:
1. When did you first recognise a problem?
2. What information did you use to assess renal function?
3. What factors influenced your choice of (medication 
name) as an alternative medication?
4. Under what circumstances, if any, would you have dis-
continued (medication name) for this patient, rather 
than reducing the dose?
Data analysis
Goals of our analysis were to identify information cues 
that HCPs used to recognise a potential problem related 
to renally eliminated or nephrotoxic medications and 
select actions to help prevent or address the problem. For 
each interview, we used an inductive, qualitative approach 
in two stages.30 First, a human factors expert and pharma-
cist independently reviewed each transcript to create a 
decision-requirements table for each incident.28 Decision 
requirements tables are often used to analyse CTA inter-
views.27 28 Analysts met and discussed each table for each 
incident until reaching consensus. (The table template is 
found in the online supplementary table A but to main-
tain participant confidentiality, individual, completed 
tables are not shown). Second, a team consisting of two 
human factors experts, a clinical pharmacist and a phar-
macist researcher identified initial emergent themes, 
and discussed new themes until reaching consensus. 
Individuals coded data independently and any disagree-
ments were resolved through consensus.31–33 As in prior 
studies,34 35 20% of interview transcripts were analysed 
by all four individuals; the remaining transcripts were 
analysed by a human factors expert and a pharmacist on 
the team. Data were double-coded if they corresponded 
to two distinct themes.36 37 No new codes were identified 
after analysing 13 cases, which indicates adequate data 
saturation. For this stage, we used an inductive coding 
approach,33 along with NVivo software (QSR Interna-
tional, V.11), to facilitate data management and analysis.
Patient and public involvement
This study was conducted to assess renal-medication 
problems, specifically, to understand the decision-making 
processes that healthcare professionals use to detect and 
respond to these patient safety concerns. These types of 
medication problems are mostly preventable and often 
serious, which makes finding solutions a priority to 
improve patient care. Patients were not directly involved 
in this study nor were they recruited; instead, our partic-
ipants were HCPs who addressed a renal-drug problem 
for one of their patients. Our results can inform future 
enhancements of healthcare systems to provide safer care 
for patients.
results
Participants and incidents
Twenty HCPs participated in 21 interviews (table 1). Inter-
views captured renal-drug problems related to 24 distinct 
medications as some incidents involved two drugs.
Model of decision-making processes
CTA analyses informed the development of a descrip-
tive model with three overarching stages for HCPs’ 
decision-making: detect a renal-drug problem, gather infor-
mation about the problem, then act to resolve the problem 
(figure 1). Three important aspects of this model were 
Table 1 Characteristics of study participants (n=20)
Participants 
characteristics
Providers
(n=10)*
Pharmacists†
(n=10)
Gender, male: n (%) 4 (40%) 2 (20%)
Age (years): mean (SD) 48.5 (+/-11.7) 36.1 (+/-5.9)
VA experience (years): 
mean (SD)
13.3 (+/-6.5) 6.4 (+/-3.8)
Setting: n (%)
  Inpatient 3 (30%) 4 (40%)
  Outpatient 7 (70%) 6 (60%)
Practice type: n (%)
  Generalist 5 (50%) 5 (50%)
  Specialist 5 (50%)‡ 5 (50%)
*Providers: eight physicians and two nurse practitioners.
†One pharmacist participated in two interviews.
‡Providers’ specialities: nephrology, endocrinology, pulmonology, 
infectious disease and surgery.
SD, Standard deviation.
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evident. First, these stages often followed a cyclical path. 
The cyclical phenomenon was evident due to recurrence 
of renal-drug problems even after HCPs took action to 
‘resolve’ a previous problem. The longer the duration of 
use of a renally eliminated medication in the setting of 
renal insufficiency, the greater the likelihood that multiple 
dosage adjustments or substitutions will be necessary to 
ensure patient safety. For example, a pharmacist reduced 
a gabapentin dose to account for a patient’s renal insuffi-
ciency, but described planning to: monitor adverse effects 
due to drug accumulation and check the patient’s renal 
function periodically. At times, gaps in organisation and 
continuity of clinical care appeared to contribute to the 
cycles of detection of incidents, gathering of information 
and acting on findings. For example, a levofloxacin dose 
was adjusted due to a patient's renal insufficiency, but in 
an emergency-department encounter a few days later, 
the patient was ordered a higher, renally inappropriate 
dose of levofloxacin. Second, the cognitive needs of HCPs 
for each stage differed slightly depending on whether 
the medication was renally eliminated or nephrotoxic 
(figure 2). Third, a cognitive discordance was evident in 
our sample where HCPs described greater trust in the 
safety of a medication if the patient had used it for a long 
duration. This phenomenon was exemplified by one of 
the physicians who stated that he/she ‘didn’t think HCTZ/
lisinopril was the cause (of renal insufficiency) at first because…
patient had been on it for a long time, (at the) same dose for 
about 4 years’. Within our sample, we examined findings 
from prescribers versus non-prescribers, but did not find 
evidence that they relied on substantially different cogni-
tive strategies to detect and manage renal-drug problems; 
instead, interview data indicated that their strategies were 
similar.
stage 1: detect
HCPs’ vigilance was an important strategy for detection, 
where HCPs were ‘on the lookout’ for potential renal 
insufficiency and problematical medications. Specifi-
cally, they conduct ongoing and deliberate review of 
patients’ information, rather than relying on systems to 
saliently highlight unanticipated cues and bring renal-
drug concerns to their attention. Thirteen (65%) of the 
20 HCPs detected a problem via their own vigilance and 
monitoring. As one pharmacist stated, ‘there’s just certain 
medications that [I] always know to look for, so that’s just on 
Figure 2 Description of how the three stages of healthcare professionals’ renal-drug decision-making differed depending on 
whether the medication was renally eliminated or nephrotoxic. 1From 15 incidents. 2From six incidents.  3All 20 HCPs used more 
than one cue to detect each renal-drug problem. HCPs, healthcare professionals; HCTZ, hydrochlorothiazide.  
Figure 1 Descriptive model of HCPs’ decision-making 
process for renal-drug problems. This depiction is derived 
from 21 renal-drug incidents. This model illustrates the 
cyclical nature of stages that HCPs used to manage patients 
with renal insufficiency. The larger circle of the ‘detect’ stage 
reflects its important contribution to one of the three main 
study findings (ie, HCPs reliance on their own vigilance). 
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the radar list’. (See online supplementary table B for addi-
tional quotes). Their vigilance strategy often involved 
reviews of medication and laboratory tests.
Depending on the drug type, the cognitive cues for 
detection differed (figure 2). HCPs used more cues to 
detect renally eliminated drugs compared with cues to 
detect nephrotoxic drugs (figure 2). For renally elimi-
nated drugs, a frequent cue that helped HCPs detect an 
inappropriate medication was recognising a high medi-
cation dose. A pharmacist stated, “(the) patient (was) on 
300 mg three times daily gabapentin, and my reaction was, ‘I’m 
sure that that’s probably too much for him’”. Additional cues 
included risk factors known to worsen renal function, 
such as older age, signs of dehydration, recent surgery or 
dialysis treatment. With one exception, all nephrotoxic 
drugs were detected by noticing an abnormal laboratory 
test result. In particular, extremely high serum creatinine 
(SCr), a SCr value higher than the patient’s baseline, or 
an increase in SCr over a short period, prompted HCPs to 
look for the cause of patients’ decline in renal function.
stage 2: gather information
In almost all incidents (20/21, 95%), HCPs gathered 
additional information about patients’ medications 
(figure 2 and online supplementary table C) using their 
clinical experience and knowledge, reviewing drug infor-
mation references, consulting a pharmacist, reading 
EHR notes or discussing directly with the patient. An 
important challenge that HCPs encountered while gath-
ering information was the lack of consistency in drug 
resources. For example, a pharmacist participant found 
two different recommendations for dosing colchicine 
in dialysis patients, one reference recommended 0.3 mg 
twice a week and the other recommended 0.6 mg and 
not repeating for 2 weeks. HCPs sometimes checked to 
confirm the indication for a renally problematical drug. 
For example, for antibiotics, they reviewed microbial 
cultures, and for gabapentin, they looked for reasons 
for the original prescription. The information the HCPs 
gathered differed depending on the type of drug. For 
renally eliminated medications, HCPs sometimes investi-
gated whether the patient was experiencing a side effect 
as a result of drug accumulation; for example, ‘patients 
can get rhabdomyolysis if [they] overdose on fenofibrate, which 
is serious’, and ‘both nitrofurantoin (in presence of renal insuf-
ficiency) and UTI [urinary tract infection] can independently 
cause an older patient to be disoriented’. HCPs also gathered 
information about renal clearance thresholds and renal 
doses to assess whether the patient’s medication dose 
needed adjustment. On the other hand, for nephrotoxic 
drugs, HCPs tended to gather information about the 
need for continued therapy and about safer treatment 
alternatives, as necessary.
In 95% (20/21) of incidents, HCPs also gathered 
information about patients’ renal function: they usually 
reviewed SCr or renal function estimates (eg, eGFR, esti-
mated creatinine clearance (eCrCl)) provided in the 
EHR (n=16 incidents), or they calculated estimated renal 
function (n=4 incidents). Looking up patients’ renal 
function was especially important to HCPs if patients 
were older, on dialysis, or taking a renally eliminated 
medication that might require a dose adjustment. HCPs 
also checked for particular patterns in SCr changes or 
trends over the last three to four laboratory tests (eg, 
‘almost doubled’, ‘big change’, ‘going up’). Several phar-
macists (n=3) expressed that CrCL estimates were most 
useful, and perceived them as a ‘standard’ for deciding if 
medication dose adjustment is needed and for selecting 
appropriate doses. As one pharmacist explained, ‘[I] 
calculate CrCL because when you look up drug information like 
in Micromedex or like Lexicomp for the package insert, when 
they (provide guidelines) about renal adjustment, it usually goes 
off a creatinine clearance, not so much a serum Creatinine, or 
eGFR’. Thus, HCPs always took the time to calculate CrCL 
estimates if the patient was on medication that required 
renal adjustment. HCPs explained that estimating renal 
function can get ‘tricky’ in older patients, underweight 
patients and in amputees.
stage 3: act
HCPs’ medication-related actions to resolve renal-drug 
problems included reducing the medication dose or 
frequency, discontinuing the medication or substituting 
the medication with an alternative (table 2). Other 
actions, that did not involve medication changes, that 
HCPs took were to continue the medication, follow-up on 
the patient’s case (eg, monitor renal function, co-morbid 
diseases) or document communications with other HCPs. 
(See online supplementary table C for additional quotes). 
HCPs’ descriptions of the factors that led to these actions 
are described in table 3. Actions differed depending on 
the drug type (figure 2).
DIsCussIOn
Our results identified three promising areas for system 
enhancements. First, the cyclical nature of the deci-
sion-making process (figure 1) highlights the impor-
tance of tools to track and detect renal-drug problems 
for patients longitudinally. This cyclical phenomenon 
found in our study was, in part, due to the progres-
sive nature of patients’ renal dysfunction, which often 
continues to decline, with medications requiring adjust-
ment over time. HCPs' actions, such as dose adjustments, 
can be falsely reassuring, because they may not lead to 
sustained, safe medical treatment for this patient popu-
lation. Our study elucidated this safety cognitive discor-
dance, and we did not find this articulated by other 
literature, suggesting this finding is a novel contribution 
of our research. We also did not find evidence in the liter-
ature of prescribing-related interventions (technology 
based or otherwise) that systematically accounts for the 
cyclical nature of renal-drug problems. Our results indi-
cate that efforts to support the cyclical aspect of renal-
drug decision-making are likely to improve patient safety. 
Although we examined a specific problem, renal-drug 
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safety applies to a large patient population. More than 
15% of all adults in the USA (30 million people) have 
chronic kidney disease.38 Additionally, we expect that our 
findings can inform other chronic diseases (eg, diabetes, 
cardiovascular diseases, chronic obstructive pulmonary 
disease) that do not necessarily have a cyclical nature 
but often worsen with patients’ age and require regular 
monitoring and medication adjustments over time. Our 
Table 2 Medication-related actions that HCPs made to help address a renal-drug problem (n=21 incidents)
Incidents
Medication-related actions
Decrease dose Decrease frequency Discontinue Substitute
Colchicine 1.2 mg, 0.6 mg in an 
hour → 0.6 mg, may 
repeat in 2 weeks
Enoxaparin 40 mg daily → 30 mg 
daily
Fenofibrate* 145 mg → 48 mg
Fenofibrate Fenofibrate
Gabapentin 600 mg tid → 600 mg 
bid
Gabapentin 800 mg bid → 600 mg 
bid
Gabapentin 300 mg tid to 600 mg 
bid
Levofloxacin† 500 mg daily → 250 mg 
daily
Lisinopril/HCTZ Lisinopril/HCTZ
Lisinopril Lisinopril temporarily 
held
Lisinopril Lisinopril
Losartan Losartan
Metformin 500 mg qid → 500 mg 
tid
Naproxen Naproxen
Nitrofurantoin → Cephalexin
Piperacillin/tazobactam, 
famotidine
Piperacillin/tazobactam: 
3.375 g q6h → 2.25 g 
q6h
Famotidine:
20 mg bid → 20 mg 
daily
Piperacillin/tazobactam → oral antibiotic
Ranitidine, fenofibrate fenofibrate Ranitidine → 
pantoprazole
Tenofovir in combination 
tablet (efavirenz 
+  emtricitabine)
→ abacavir containing 
combo pill
Valganciclovir 900 mg → 450 mg bid → daily
Vancomycin, piperacillin/
tazobactam
Vancomycin: initial 
dose at 1250 mg 
q12h, held 1 day, 
restart at 1250 mg 
daily
piperacillin/
tazobactam
Total=24 drug problems 6 6 8 4
Except for one incident involving valganciclovir, HCPs made one medication-related action per renal-drug problem.
*co-occurring with concern for fenofibrate-simvastatin drug-drug interaction.
†co-occurring with concern for levofloxacin-prednisone drug-drug interaction.
bid, two times per day; HCPs, healthcare professionals, HCTZ, hydrochlorothiazide; qid, four times per day; q6h, every 6 hours; q12h, every 
12 hours, tid, three times per day. 
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Table 3 Summary of actions and decisions taken by HCPs and the factors associated with these decisions
Action Associated factors that prompted the action
Reduce dose or frequency  ► Selected convenient dosing regimen for patient to enhance medication adherence (eg, 
pharmacist selected longer dosing interval that avoided need for the patient to split tablets as 
this be can confusing and difficult for patients)
 ► Followed guideline recommendations for dose reduction
 ► Selected a safer, reduced dose to account for patient’s older age, since older age is often 
associated with renal function decline
 ► Reduced dose or frequency of a renally eliminated drug to minimise drug accumulation and 
thus, avoid adverse effects for the patient
Discontinue HCPs discontinued drug because:
 ► Renal function was below a certain threshold (eg, CrCL<60 mL/min prompted HCP to 
discontinue nitrofurantoin; proteinuria prompted discontinuation of tenofovir)
 ► Patient’s medication was not critically needed for therapy (eg, no apparent medication 
indication, medication was not effective for the patient)
 ► Patient has other risk factors that can worsen renal function (eg, older age, diabetes mellitus, 
hypertension, dehydration)
 ► The risks associated with stopping or temporarily withholding medication therapy were 
perceived as minimal (eg, low risk of antibiotic resistance with discontinuation of nitrofurantoin)
Substitute HCPs substituted drug because:
 ► Alternative treatments existed that were not nephrotoxic or renally eliminated, were less 
expensive, or were non-pharmacological
 ► It was not a viable option to discontinue medication therapy altogether (eg, still needed to 
treat the patient’s pain after discontinuing naproxen; manage hypertriglyceridaemia after 
discontinuing fenofibrate; manage hypertension after discontinuing lisinopril)
 ► The need for original medication was not as critical (eg, switched from piperacillin/tazobactam 
to amoxicillin/clavulanic acid when bacterial culture was negative)
Continue  ► Renal function was still above a certain, acceptable threshold
 ► Determined that the medication was needed for patient treatment, and HCP perceived that the 
benefits of continuing outweigh risks (eg, a combination pill containing tenofovir continued for a 
few weeks despite renal concerns, to prevent gaps in treatment. It was later discontinued due to 
worsening renal function)
 ► Alternative medications were non-formulary (eg, gabapentin was continued to treat peripheral 
neuropathy rather than switched to duloxetine or pregabalin because they ‘require special 
approval’)
 ► Suspected that another medication was the primary reason for renal injury (eg, HCP continued 
lisinopril/HCTZ because he believed that NSAIDs were more likely the cause of renal injury, 
since the patient had been on lisinopril/HCTZ for a long time. SCr continued to worsen, 
however, and HCP then discontinued lisinopril/HCTZ)
Follow-up  ► To assess whether renal function improved after the HCP took action to address the renal-drug 
problem (eg, on stopping, reducing dose or holding a dose of an offending drug)
 ► To counsel the patient (eg, about fluid intake, to confirm that the patient has stopped the risky 
medication)
 ► To follow-up on co-morbid conditions that can worsen renal function (eg, work on controlling 
diabetes mellitus and hypertension)
 ► To monitor patients’ health condition after discontinuing medication therapy (eg, monitor 
triglycerides after discontinuing fenofibrate, monitor blood pressure after discontinuing lisinopril)
Document To make other HCPs, typically the prescriber or patient’s primary care physician, aware of the 
following:
 ► Patient’s impaired renal function
 ► Their recommendations to reduce a medication dose or substitute a medication
 ► Their decision to discontinue a medication and their associated reasoning
 ► To add clarification about the patient’s medication list following hospital discharge (eg, to 
emphasise that lisinopril, which was nephrotoxic to the patient, is absent from the list)
 ► Communication with, and counselling of, the patient regarding prescription and over-the-
counter medications that should be avoided
CrCL, creatinine clearance; HCPs, healthcare professionals; HCTZ, hydrochlorothiazide; NSAIDs, non-steroidal anti-inflammatory drugs; SCr, 
serum creatinine.
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findings may also inform more effective software solu-
tions to aid attention, memory and perception, and thus 
provide cognitive support to help prevent prescription 
errors more generally.
Second, HCPs often relied on their own vigilance 
to detect a renal-drug problem. However, vigilance is 
recognised by the scientific community as a fallible, 
tedious and difficult strategy for individuals to effectively 
maintain to monitor and detect patient safety related 
problems.39 Moreover, vigilance is especially inadequate 
if cues lack sufficient salience.39 HCPs divert their mental 
energy to find renal-drug problems, while their cognitive 
capacity is needed for other complex clinical tasks. The 
detection stage of renal-drug decision-making is crucial 
(figure 1), because there is no way to prevent or mitigate 
a renal-drug problem if the issue remains unnoticed. 
Thus, there is a need for more robust, system-level solu-
tions to aid HCP’s detection of these problems. Much 
research in the literature has focused on developing 
more accurate measures of renal function,40–42 but our 
findings, along with reports of high rates for inappro-
priate prescribing,1 7 9 indicate that much more effort is 
needed to develop systematic interventions to help HCPs 
detect renal-drug problems when it is already established that 
the patient has renal insufficiency. This could include 
improved EHR visualisations and information represen-
tation, which could shift focus from standard numerical 
values to depicting graphical trends and/or the magni-
tude of change over time for the patients’ renal function.43 
In addition to EHR medication alerts, which generally 
appear during prescribing processes,44 safety for this 
patient population may be improved via mechanisms 
that support more regular, focused follow-up and moni-
toring. Specifically, monitoring is warranted to detect 
emergent renal-drug problems for renally eliminated and 
nephrotoxic medications that occur between prescribing 
intervals, since during those times, renal function may 
decline below important medication safety thresholds. 
Additionally, to aid safety, it may be warranted to restrict 
renally eliminated and nephrotoxic medication prescrip-
tions to reduced, limited quantities and fewer number 
of refills for patients with known renal impairment. Our 
results indicate that efforts to further reduce reliance on 
HCPs’ vigilance (beyond alert interventions), are likely to 
improve safety for patients with renal impairment. We did 
not find alert fatigue to be a notable factor for renal-drug 
problems, most likely because VA’s CPOE system provides 
only limited renal alerts.21 Additionally, our study exam-
ined decision-making for renal-drug problems broadly, 
regardless of whether or not CPOE alerts were involved in 
the incident. In the incidents we collected, HCPs detected 
problems not just during prescribing, but at other points 
of the medication use process, which typical CPOE alerts 
cannot detect. Our findings are important because 
they provide evidence that can inform future enhance-
ments of alerts. Future studies could also build on our 
findings and implement patient education programmes 
to empower patients with knowledge on how to detect 
potential renal-drug problems and the importance of 
regular follow-up.
Third, computerised decision support features in 
EHRs, such as medication alerts, should account for 
differences in HCPs’ cognitive needs for renally elimi-
nated versus nephrotoxic medications (figure 2). One 
study implemented alerts in a hospital’s CPOE system in 
an effort to improve prescribing for patients with renal 
impairment.45 The researchers used a semi-automated 
process where pharmacists received alerts and then could 
enter recommendations into a progress note in the EHR. 
However, they did not articulate or discuss the different 
decision-making or alert content needs between the two 
types of renal-drug problems.45 Similarly, a pilot study 
conducted in three types of clinical settings (geriatrics, 
internal medicine and outpatient care) implemented 
an alert system to reduce renally inappropriate prescrip-
tions.46 Their alerts provided recommendations for renal 
dosing and discontinuing drugs, which were perceived as 
useful by physicians. However, the study did not indicate 
if those alerts and associated recommendations differed 
according to the type of renal-drug problem.46 Our study 
suggests that for renally eliminated medications, providers 
need information on dosage reductions; for nephrotoxic 
medications, providers need information on safe drug 
alternatives. Future, tailored approaches to clinical deci-
sion support that distinguishes between these two types 
of renal-drug problems may substantially reduce inappro-
priate prescriptions for patients with renal insufficiency.
Our study has limitations. First, it was conducted at 
one large VA Medical Centre, so our findings may not 
always generalise to other healthcare settings, although 
we have no evidence that our findings or HCP’s cogni-
tive needs are unique to this healthcare organisation. 
Second, the VA’s EHR system is capable of alerting HCPs 
about the patient’s renal impairment at the start of medi-
cation ordering process,21 but does not offer real-time 
renal alerts for specific medication orders other than 
metformin, a state that likely led to less problem detec-
tion via computerised alerts in our sample. Our broader 
focus on HCPs’ cognitive strategies and cues rather than 
studying alert design and technical aspects of the VA’s 
EHR, however, makes this limitation less of a concern. 
Third, HCPs submitted renal-drug incidents voluntarily, 
and since the study focused on medication problems, 
some individuals might have avoided participation even 
though we examined cases where participants inter-
vened. Thus, the voluntary nature of this study might 
have influenced the sample of participants and type of 
incidents we captured. For instance, HCPs might have 
submitted incidents for which they felt the most confi-
dent that they had taken the best course of action for the 
patient. However, this sampling strategy was specifically 
selected as it aligns with our objective of examining HCPs 
cognitive strategies for situations where errors and poten-
tial safety concerns were caught and addressed. Fourth, 
although we intended to compare cognitive cues used 
by prescribers versus non-prescribers, we could not find 
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differences in their decision-making processes, perhaps 
due to the wide variation in patient cases. Finally, recall 
bias might have occurred for HCPs, since we conducted 
follow-up interviews after the incident. The adaptations 
that we made to the CTA, however, were intended to stim-
ulate recall and aid data collection accuracy.19
COnClusIOn
This study yielded a descriptive model of the deci-
sion-making process that HCPs used to manage renal-
drug problems in patients with renal insufficiency. This 
model is expected to be useful for medical, pharmacy 
and nursing trainees and residents to help them gain 
familiarity with HCPs’ processes for managing renal-
drug problems. Based on the findings, improvements 
are warranted for three areas of healthcare systems: (1) 
support the cyclical nature of the three main stages of 
renal-drug problem management via more robust, longi-
tudinal safety mechanisms for individual patients, (2) 
provide tools to alleviate HCPs’ heavy reliance on their 
own vigilance to detect patients’ renal-drug problems, 
which is mentally demanding and potentially error-prone 
and (3) develop systems to support HCPs’ distinct deci-
sion-making needs for renally eliminated versus neph-
rotoxic medications. Our findings can inform systems to 
mitigate renal-drug problems; thus providing safer care 
for patients.
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